Prince Pharmaceutical Co., Ltd. (6935.TWO)
- Previous Close
21.35 - Open
20.80 - Bid 20.40 x --
- Ask 21.10 x --
- Day's Range
20.40 - 20.90 - 52 Week Range
18.50 - 30.20 - Volume
16,200 - Avg. Volume
14,196 - Market Cap (intraday)
750.402M - Beta (5Y Monthly) 0.43
- PE Ratio (TTM)
-- - EPS (TTM)
-1.46 - Earnings Date --
- Forward Dividend & Yield 0.25 (1.17%)
- Ex-Dividend Date Jun 21, 2024
- 1y Target Est
--
Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin c tablets, vitamin b complex tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufenamate, bisbentiamine, thiamine disulfide, potassium guaiacolsulfonate, potassium cresolsulfonate, fusultiamine hydrochloride, and fursultiamine. It supplies its products to Spain and Europe. Prince Pharmaceutical Co., Ltd. was founded in 1962 and is headquartered in Yunlin County, Taiwan.
www.prince-pharm.com.tw210
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 6935.TWO
View MorePerformance Overview: 6935.TWO
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6935.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6935.TWO
View MoreValuation Measures
Market Cap
781.52M
Enterprise Value
1.14B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.13
Price/Book (mrq)
1.08
Enterprise Value/Revenue
1.65
Enterprise Value/EBITDA
55.11
Financial Highlights
Profitability and Income Statement
Profit Margin
-7.76%
Return on Assets (ttm)
-2.24%
Return on Equity (ttm)
-7.16%
Revenue (ttm)
690.03M
Net Income Avi to Common (ttm)
-53.54M
Diluted EPS (ttm)
-1.46
Balance Sheet and Cash Flow
Total Cash (mrq)
102.8M
Total Debt/Equity (mrq)
63.82%
Levered Free Cash Flow (ttm)
42.18M